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Abstract
N-Ras is one member of a family of oncoproteins that are commonly mutated in cancer.
Activating mutations in N-Ras occur in a subset of colorectal cancers, but little in known about
how the mutant protein contributes to onset and progression of the disease. Using genetically
engineered mice, we find that mutant N-Ras strongly promotes tumorigenesis in the context of
inflammation. The pro-tumorigenic nature of mutant N-Ras is related to its anti-apoptotic
function, which is mediated by activation of a non-canonical MAPK pathway that signals through
Stat3. As a result, inhibition of MEK selectively induces apoptosis in autochthonous colonic
tumors expressing mutant N-Ras. The translational significance of this finding is highlighted by
our observation that NRAS mutation correlates with a less favorable clinical outcome for
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colorectal cancer patients. These data demonstrate for the first time the important role that N-Ras
plays in colorectal cancer.\
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INTRODUCTION
The Ras protein family consists of four highly homologous enzymes (H-Ras, N-Ras, K-
Ras4A, and K-Ras4B) that are identical over the first 85 amino acids, 85% identical over the
next 80 amino acids, and largely divergent within the C-terminal 24 amino acids, a domain
that is referred to as the hypervariable region (HVR). Proteins of the Ras family act as GDP/
GTP-regulated switches to mediate cellular responses to extracellular signals (1). When
bound to GTP, Ras proteins assume a conformation that allows them to engage and activate
a multitude of downstream effectors. Each of the Ras isoforms can be locked into its GTP-
bound activated state via missense mutation, typically at amino acid 12, 13, or 61 (2).
Mutant Ras proteins accumulate in the GTP-bound conformation due to defective intrinsic
GTPase activity and/or resistance to inactivation by GTPase activating proteins (GAPs) (3).
Such activating mutations are common in human cancers.
Consistent with the high degree of homology shared by members of the family, biochemical
assays have failed to uncover significant differences between Ras isoforms. Nevertheless,
genetic studies have revealed apparent isoform-specific phenotypes. In human cancers, for
example, mutations in different RAS genes are preferentially associated with distinct tumor
types. KRAS mutations are extremely common in cancers of the pancreas, colon, and lung,
while NRAS mutations predominate in melanoma and hematopoetic cancers (4). Given the
highly conserved enzymatic function of the Ras isoforms, it remains unclear what accounts
for their differing mutational frequencies. Whereas variable expression levels and/or patterns
in specific tissues might underlie some of the observed biological differences (5), emerging
evidence supports the idea that each Ras isoform is truly functionally unique. For example,
we reported the generation of mice genetically engineered to express mutationally activated
N-Ras (N-RasG12D) and K-Ras (K-RasG12D) specifically in the intestinal epithelium (6).
While activating mutations in K-Ras occur in 40% of human colorectal cancers (CRCs), N-
Ras mutations occur in only 3% (7–9). In the mouse colonic epithelium, K-RasG12D induces
hyper-proliferation that manifests as chronic intestinal hyperplasia and, in the context of
mutant Apc, strongly enhances the transition from a benign adenoma to a malignant
adenocarcinoma. By contrast, N-RasG12D does not affect basal homeostasis or tumor
progression, but instead inhibits the ability of intestinal epithelial cells to undergo apoptosis
in response to stress (6). Presently, it is unclear if/how the anti-apoptotic phenotype
associated with mutationally activated N-Ras contributes to the initiation and progression of
CRC.
Because N-Ras is the least studied of the Ras family GTPases, its isoform-specific
oncogenic properties are not well characterized. Unlike K-Ras and H-Ras, N-Ras is not
activated by specific cytokines (e.g. IL-3) or growth factors (e.g. EGF) (10). In myeloma
cells, however, expression of mutationally activated N-Ras produces a transcriptional
response similar to treatment with IL-6 (11, 12). Although loss of mutant N-Ras in some cell
types is associated with a reduction in proliferation (13), N-Ras function has also been
linked to the regulation of apoptosis. For example, knockdown of mutant N-Ras in
melanoma cells causes apoptosis, suggesting that mutant N-Ras provides a steady state
survival signal (14). In our study, we have examined the molecular mechanisms underlying
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the anti-apoptotic function of N-Ras in colonic epithelial cells and connected these
mechanisms to the ability of mutant N-Ras to promote CRC.
RESULTS
Activated N-Ras Promotes CRC in the Context of Inflammation
We have previously shown that expression of N-RasG12D in the colonic epithelium has no
effect on basal homeostasis, but instead protects the epithelium from apoptosis induced by
acute exposure to dextran sodium sulfate (DSS) (6). Based on this observation, we
hypothesized that NRAS mutations might arise in CRC under circumstances of chronic
apoptotic stimulus. Inflammation is a strong risk factor for CRC and it can also promote
apoptosis of epithelial cells (15). To determine whether activated N-Ras affects colonic
epithelial homeostasis in the context of inflammation, we induced colitis in N-Ras wild-type
(Villin-Cre, referred to as WT) and N-Ras mutant (Villin-Cre; NrasLSL-G12D/+) animals by
treating them with cycles of DSS (5 days on, 10 days off). Animals expressing N-RasG12D
were relatively resistant to the chronic effects of DSS, as measured by weight loss and
activation of T cells in the mesenteric lymph nodes (Supplementary Fig. S1A–C). And while
Villin-Cre; NrasLSL-G12D/+ animals developed lower grade inflammation than WT mice, the
colonic epithelium was hyperproliferative in N-Ras mutants compared to WT animals
(Supplementary Fig. S1D). These observations indicate that expression of mutant N-Ras in
the colonic epithelium plays a dual role in this mouse model: (1) it suppresses the initial
DSS-induced apoptosis that is required for the initiation of colitis and (2) it promotes hyper-
proliferation in the context of colitis.
In WT mice, the extent of colitis typically increases as animals receive sequential cycles of
DSS. After 9 cycles of DSS, our WT animals developed severe colitis that was associated
with epithelial damage and bleeding ulcers (Fig. 1A,B). The colitis that developed in
animals expressing N-RasG12D was markedly reduced, although focal regions of
inflammation were present (Fig. 1A,B). Remarkably, half of the animals expressing N-
RasG12D (but none of the WT controls) developed colonic adenocarcinomas exhibiting high
levels of nuclear β-catenin (Fig. 1A,C), suggesting that activated N-Ras promotes CRC
driven by inflammation.
An alternative way to induce CRC driven by inflammation is to pre-treat animals with a
single dose of the colon-specific carcinogen azoxymethane (AOM), followed by three cycles
of DSS (16). Under this protocol, 5/7 WT animals developed colonic tumors, with most
animals developing just a single macroscopically visible tumor (Fig. 1D). All of the animals
expressing N-RasG12D (12/12) developed at least a single tumor, with most animals
developing multiple (Fig. 1D). Histologically, the tumors expressing mutant N-Ras were not
clearly different from those expressing wild-type N-Ras (Fig. 1E, Supplementary Fig. S1E).
One explanation for this observation is that AOM/DSS-induced tumors from WT mice
acquire N-Ras mutations. To explore this concept, we sequenced exons 2 (containing amino
acids 12/13) and 3 (containing amino acid 61) of Nras in tumors from WT mice treated with
AOM/DSS. We found zero mutations in 21 tumors that were evaluated, indicating that Nras
is not commonly mutated in AOM/DSS-induced tumors from WT animals.
Since mutant N-Ras enhanced proliferation of the normal epithelium in the context of
inflammation, we expected N-Ras mutant tumors to be hyper-proliferative relative to those
that developed in a WT background. Unexpectedly, they were not (Supplementary Fig. 1F).
Consistent with our previous observation that N-RasG12D suppresses stress-induced
apoptosis, however, we did detect a difference in the basal levels of apoptosis in WT and N-
Ras mutant colonic tumors (Fig. 1F). Altogether, these observations suggest that
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mutationally activated N-Ras promotes CRC by suppressing the chronic apoptotic stimulus
provided by inflammation.
Mutant Forms of Ras Exhibit Unique Apoptotic Phenotypes and Signaling Properties
To uncover the molecular mechanisms underlying the anti-apoptotic function of N-Ras, we
generated human colonic epithelial cell lines that differ in their Ras genotype. While these
cell lines expressed similar levels of Ras (Supplementary Fig. S2), they differed
significantly in their ability to enhance proliferation and to suppress apoptosis - only mutant
K-Ras induced hyper-proliferation (Supplementary Fig. S3A), while only mutant N-Ras
suppressed apoptosis in response to butyrate, a carboxylic acid that induces cell death
through both intrinsic and extrinsic apoptotic pathways (Fig. 2A, Supplementary Fig. S3B).
These data are consistent with our previous observations that mutant N-Ras alone can
function to suppress apoptosis in colonic epithelial cells (6, 17).
Since there are no known human colorectal cancer cell lines expressing mutationally
activated N-Ras, our experiments relied on cell lines in which N-RasG12D was ectopically
expressed from a retrovirus. A caveat to these studies is that the anti-apoptotic phenotype
associated with mutant N-Ras might be due to over-expression, rather than due to a true
functional difference among family members. To address specifically whether the mutant N-
Ras in our CRC cell line was over-expressed relative to endogenous mutant N-Ras found in
other cancers, we performed Ras activity assays on a panel of cells lines (Supplementary
Fig. 4A). This analysis confirmed that the levels of N-Ras•GTP in our CRC cells are
comparable to the levels found in cell lines expressing endogenous mutant N-Ras.
Mutant forms of Ras are thought to engage multiple downstream effectors in order to
transmit their oncogenic signal. To determine whether mutant N-Ras exhibits unique
signaling properties when compared to mutant K-Ras and H-Ras, we used quantitative
western blotting to measure the effects of Ras activation on downstream effector pathways
in serum-starved cells (Supplementary Fig. S4B). N-RasG12D activated ERK and AKT
(relative to WT), but failed to activate RALA, JNK, or P38 MAPK (Fig. 2B). The signaling
properties associated with mutant K-Ras differed somewhat from mutant N-Ras, for
example in the activation of AKT, but H-Ras appeared to exhibit identical signaling
properties to that of N-Ras (Fig. 2B). Although this signaling analysis did not reveal whether
a specific pathway is required for N-Ras function, it did demonstrate that the phenotypic
differences between N-Ras and the other family members (e.g. H-Ras) cannot be explained
by differential signaling through canonical effector pathways.
N-Ras Signals Specifically Through RAF-1 to Suppress Apoptosis
While N-RasG12D is clearly able to engage multiple downstream pathways, it remained
unclear whether activation of a particular effector pathway is necessary or sufficient to
mediate its anti-apoptotic phenotype. To address this issue, we generated cell lines
expressing N-RasG12D along with a secondary mutation that restricts signaling to a
particular effector pathway (Supplementary Fig. S2) - the T35S mutant binds preferentially
to RAF, the E37G mutant shows preference for RALGDS, and the Y40C mutant binds
preferentially to PI3K (18). N-RasG12D/T35S fully phenocopied N-RasG12D with respect to
its ability to confer resistance to butryate-induced apoptosis (Fig. 2C). This observation
indicates that binding to RAF is sufficient for mutant N-Ras to protect cells from apoptosis.
To confirm this result, we pretreated cells with AZ-628, a pan-RAF inhibitor, prior to
induction of apoptosis with sodium butyrate. Inhibition of RAF had no effect on the
apoptotic phenotype of WT cells, but reversed the anti-apoptotic phenotype of N-RasG12D
(Fig. 2D), indicating that RAF signaling is required downstream of N-RAS.
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RAF is a protein family that consists of three highly related serine/threonine kinases, A-
RAF, B-RAF, and C-RAF (also called RAF-1). To determine whether one RAF family
member mediates the N-Ras anti-apoptotic phenotype, we used lentivirus-mediated shRNA
to knock down RAF levels in cells expressing wild-type or mutant N-Ras (Supplementary
Fig. S5A). Knockdown of RAF-1, but not A-RAF or B-RAF, reverted the N-Ras phenotype
toward that of WT (Fig. 2E, Supplementary Fig. S5B), suggesting that RAF-1, in particular,
mediates the anti-apoptotic function of N-RasG12D. To explore this concept further, we
expressed different activated forms of RAF in CRC cells that were wild-type for N-RAS.
Expression of mutationally activated RAF-1 protected cells from butyrate-induced apoptosis
to the same extent as activated N-Ras (Fig. 2F). Expression of B-RAF or A-RAF did not
phenocopy N-Ras, even though all three forms of RAF could activate ERK to the same
extent (Fig. 2F,G).
Altogether, our data have demonstrated that N-Ras alone suppressed butyrate-induced
apoptosis, even though all of the Ras family members could activate ERK (Fig. 2B).
Moreover, we found that RAF-1 was also unique within the RAF kinase family in its ability
to suppress apoptosis, while all of the RAF family members activated ERK to roughly the
same extent (Fig. 2G). Based on these observations, we considered the possibility that (1) a
MEK/ERK-independent pathway functions cooperatively downstream of N-Ras/RAF-1 to
suppress butryate-induced apoptosis or (2) a non-canonical MAPK pathways was mediating
the anti-apoptotic function of mutant N-Ras.
N-Ras Mediates IL-6→Stat3 Signaling
Mutationally activated N-Ras can confer cytokine-independent growth upon previously
IL-6-dependent cell lines (11, 12). Studies of mouse models have also demonstrated that
IL-6 signaling also plays an important role in inflammation-driven CRC (19, 20). By
extension, we explored whether N-Ras actively functions within the IL-6 signaling pathway
to control the response of CRC cells to apoptotic stimuli. To begin, we treated WT and
mutant cells with exogenous IL-6. When exposed to IL-6, cells expressing wild-type N-Ras
became partially resistant to butyrate-induced apoptosis (Fig. 3A). IL-6 treatment failed to
further protect cells expressing mutant N-Ras, suggesting that the downstream pathway
activated by IL-6 was already activated in cells expressing N-RasG12D (Fig. 3A).
The primary downstream effector of IL-6R function is the Stat3 transcription factor (21).
Cells expressing N-RasG12D or RAF-1Y340/341D expressed two-fold higher levels of Stat3
phosphorylated on Tyr705 than did cells expressing wild-type Ras or mutant forms of K-Ras
and H-Ras (Fig. 3B). Surprisingly, although ERK was highly activated in cells expressing
mutant N-Ras, there was no change in the phosphorylation state of Ser727, an ERK
phosphorylation site (Supplementary Fig. S6A). Stat3 is a transcription factor that regulates
the expression of genes involved in proliferation and survival (21). We found that CRC cells
expressing mutant N-Ras expressed higher levels of the canonical Stat3 target genes
CCND1 and SOCS3 relative to WT (Fig. 3C). Similarly, we found that genes negatively
regulated by Stat3 (IFIT3 and IFI35) were expressed at lower levels in cells expressing N-
RasG12D (Fig. 3C).
We next analyzed the apoptotic phenotypes of WT and mutant cells that lack Stat3. Similar
to loss of RAF-1, loss of Stat3 reverted the N-Ras phenotype, but had no significant effect
on the butyrate response of WT cells (Fig. 3D). We also found that a small molecule
inhibitor of Stat3 (Stattic) could also revert the apoptotic phenotype of N-Ras mutant cells to
WT (Fig. 3E). Taken together, our results indicate that mutant N-Ras signals through Stat3
to regulate the cellular response to butyrate.
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Our data suggested that N-RasG12D suppresses apoptosis by activating RAF-1 and Stat3, but
it was unclear whether these signals were dependent or independent of one another. To
explore this question, we examined the phosphorylation status of Stat3 in cells that were
treated with CI-1040, a MEK inhibitor (22). MEK is the only bona fide effector of RAF
signaling. Inhibition of MEK led to a decrease in the phosphorylation status of Stat3 in cells
expressing N-RasG12D (Fig. 3F). Alternatively, shRNA-mediated knockdown of Stat3 had
no effect on the activation state of ERK (Supplementary Fig. S6B). These data suggest that
N-RasG12D activates Stat3 downstream of MEK.
N-RAS•GTP Forms a Complex with RAF-1 and Stat3
How does N-Ras activate Stat3 and why is it the only family member that can do so? One
possibility is that mutant N-Ras induces an autocrine IL-6 feedback loop that activates Stat3
downstream of IL-6R. Contrary to this hypothesis, we did not detect an increase in secreted
IL-6 in the culture media of cells expressing N-RasG12D (Supplementary Fig. S6C).
Moreover, conditioned medium from cells expressing mutant N-Ras was not able to activate
Stat3 in WT cells (Supplementary Fig. S6D). Based on these data, we believed that it was
more likely that mutant N-Ras was directly activating Stat3 by forming a complex with it.
Indeed, we found that N-RasG12D, but not K-RasG13D nor H-RasG12V, co-
immunoprecipitated with Stat3 (Fig. 3G, Supplementary Fig. S6E,F). Consistent with our
observation that mutant RAF-1 also activated Stat3, RAF-1 immunoprecipitated with Stat3
(Supplementary Fig. S6G). These results indicate that activated N-Ras forms an anti-
apoptotic signaling complex that includes Stat3 and RAF-1.
Mutant N-Ras Signals From Cholesterol-rich Microdomains to Suppress Apoptosis
Mutant forms of N-Ras and H-Ras are equal in their ability to activate ERK, but only N-Ras
can activate Stat3. We hypothesized that their differing abilities to activate Stat3 may result
from a difference in sub-cellular localization. Consistent with this hypothesis, replacing the
H-Ras HVR with that of N-Ras allowed H-Ras to suppress butyrate-induced apoptosis,
suggesting that the anti-apoptotic phenotype of mutant N-Ras is specified by its localization
(Fig. 4A). On the plasma membrane, GTP-bound forms of N-Ras and H-Ras are thought to
differ in their distributions among cholesterol-rich microdomains (23, 24). Following
biochemical purification, we found that mutant N-Ras, but not mutant H-Ras, could be
detected in caveolin-rich fractions (Fig. 4B). Consistent with our proposed mechanism of
action of mutant N-Ras, we found that ERK and Stat3 were highly enriched in the same
fractions as N-Ras (Fig. 4B). Caveolae can be dissociated by exposure to filipin, an
antifungal agent isolated from Streptomyces filipensis, or to methyl-β-cyclodextrin
(MβCD). The ability of N-Ras to co-immunoprecipitate with Stat3 was affected by
treatment of cells with filipin (Fig. 3G) and transient exposure to filipin or MβCD abrogated
the anti-apoptotic phenotype of mutant N-Ras (Fig. 4C), suggesting that, in CRC cells, N-
Ras signals from caveolae to suppress apoptosis.
Mutant N-Ras activates ERK and Stat3 in Primary Cancers
To determine whether mutant N-Ras signals through ERK and Stat3 in primary CRCs, we
examined their activation states in tumors from mice and humans by immunohistochemistry.
In tumors from AOM/DSS treated animals, there was no detectable difference in ERK
activation between WT and N-Ras mutant tumors, primarily because ERK was strongly
activated in all tumors (Fig. 5A,B). In human samples, however, CRCs expressing mutant
forms of N-Ras exhibited a dramatic enhancement of phospho-ERK staining (Fig. 5A,B). To
expand upon this observation, we used gene set enrichment analysis (GSEA) to measure
differences in gene expression between primary human CRCs that were wild-type or mutant
for N-Ras. Consistent with our IHC analysis, we found that the expression of genes related
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to MAPK signaling was significantly enriched in cancers expressing mutant N-Ras relative
to those that were wild-type (Fig. 5C).
In both mouse and human tumors, we found that mutant N-Ras strongly activated Stat3 (Fig.
5D,E). GSEA analysis failed to identify enrichment within N-Ras mutant cancers for genes
that are up-regulated by Stat3 (data not shown). Interestingly, however, genes known to be
negatively regulated by Stat3 were significantly under expressed in cancers expressing
mutant N-Ras (Fig. 5F), indicating that Stat3 transcriptional activity is enhanced in the
context of N-Ras mutation. These results are consistent with the notion that mutant N-Ras
activates the non-canonical MAPK/Stat3 signaling in primary CRC and raises the possibility
that therapeutically targeting this pathway could be an effective way to treat N-Ras mutant
cancer.
A Therapeutic Strategy for CRCs Expressing Mutant N-Ras
What is the most effective way to target the MAPK pathway therapeutically? Over the past
several years, a hanful of highly specific MEK inhibitors have entered the lab and clinic (22,
25–27). Given that we had already shown that inhibition of MEK with CI-1040 could
abrogate the activation of Stat3 downstream of N-RasG12D (Fig. 3F), we next tested whether
it could revert the anti-apoptotic phenotype associated with mutant N-Ras. As with
pharmacologic inhibition of RAF, inhibition of MEK suppressed the N-Ras apoptosis
phenotype (Fig. 6A). Next, we treated mice bearing AOM/DSS-induced tumors with
CI-1040. Acute inhibition of MEK induced apoptosis in tumors expressing N-RasG12D, but
not in WT tumors (Fig. 6B). Together, these data suggest that MEK inhibitors could be
highly efficacious for patients with N-Ras mutant CRC.
One major question that remains is: How significant is mutationally activated N-Ras to CRC
in human patients? To address this question, we determined the NRAS mutational status of
581 CRCs from patients treated at Memorial Sloan Kettering Cancer Center. Consistent with
previous reports (8, 9), we found activating mutations in NRAS in approximately 3% of
cases (17/581) (Supplementary Table S1). Importantly, when compared with patients whose
cancers were WT for NRAS, KRAS, and BRAF, patients with NRAS mutant cancers
experienced significantly worse overall survival, similar to those with mutations in KRAS
(Fig. 6C). This observation highlights the importance of identifying new therapies, for
example MEK inhibition, for CRCs expressing mutant N-Ras.
DISCUSSION
CRC is a paradigm for the cooperative action of mutations in oncogenes and tumor
suppressor genes (28). Understanding the disease at a level that will allow for a priori
prediction of viable therapeutic targets will require a mechanistic elucidation of each of the
mutational events that contribute to initiation and progression. Of particular importance is
whether specific mutational events are cooperative or redundant, or whether they may
contribute to the development of distinct subtypes of CRC. For example, based on
mutational analysis of CRC, mutations in KRAS and NRAS appear to be redundant, as they
are not typically found in the same tumor (Supplementary Table S1) (8, 9). As a result, one
might predict that a common therapeutic strategy would work for cancers that carry
mutations in either of these two genes. Yet our functional analysis demonstrated that mice
expressing mutationally activated forms of K-Ras or N-Ras in the colonic epithelium
exhibited essentially non-overlapping phenotypes (6). We interpret these observations to
mean that KRAS and NRAS mutations are mutually exclusive, not because they are
redundant, because they are selected for under distinct tumorigenic contexts. The differential
apoptotic function of N-Ras and K-Ras led us to speculate that NRAS mutations might arise
specifically under circumstances of chronic apoptotic stimulus. Indeed, our studies of
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genetically engineered mice indicated that N-RasG12D enhances colon cancer development
in the context of inflammation (Fig. 1). Both chronic, for example in inflammatory bowel
disease (IBD), and acute inflammation contribute to the progression of CRC (29).
Using both in vitro and in vivo systems, we sought to uncover the molecular mechanisms
that underlie the unique anti-apoptotic function of N-Ras. In other cell types, mutant N-Ras
has been correlatively linked to numerous survival and apoptotic pathways, including BCL2,
AKT, JNK, and p38 (30–33). Our data fail to implicate these previously identified pathways
in mediating N-Ras function in colonic epithelial cells, suggesting that the pathways utilized
by mutant N-Ras to suppress apoptosis are context dependent. Our data indicated that N-
RasG12D requires only RAF-1 to suppress apoptosis (Fig. 2C–E). While each Ras family
member is believed to bind all of the RAF family members, the specific engagement of
RAF-1 by mutant N-Ras has also been observed in melanoma cells (34). Although N-Ras
signals through RAF-1 to activate the canonical MAPK pathway, the RAF-dependent
activation of ERK was not sufficient to explain the anti-apoptotic phenotype associated with
mutant N-Ras, however. Based on previous reports of N-Ras function in myeloma cells (11,
12), we examined whether Stat3 plays a role in the anti-apoptotic function of N-Ras and
RAF-1. Indeed, cells expressing mutant N-Ras exhibit hyper-phosphorylation of Stat3 on
Tyr705 and Stat3 was required for the anti-apoptotic function of N-RasG12D (Fig. 3).
Interestingly, Stat3 was also activated by endogenous mutant N-Ras when it was expressed
in hematopoetic cells, suggesting that the non-canonical MAPK pathway may be
functioning in other contexts as well (35).
Since Stat3 functions as a transcription factor, we confirmed that it was functionally
activated by measuring the expression levels of known Stat3 targets in cell lines and primary
cancers expressing mutant N-Ras (Fig. 3C,5F). Gene set enrichment analysis (GSEA) of
mRNA expression data from human CRCs failed to identify enrichment for genes that are
up-regulated by Stat3 in cancers expressing mutant N-Ras. By contrast, GSEA identified a
significant negative enrichment for genes that are down-regulated by Stat3 in cancers
expressing mutant N-Ras (Fig. 5F). While it is somewhat difficult to interpret a lack of
correlation in GSEA (i.e. the failure to find significant over-expression of Stat3 targets), this
observation suggests that mutant N-Ras may specifically regulate the transcriptional
repressive function of Stat3. While Stat3 is primarily known as a transcriptional activator,
and many of its targets (e.g. CyclinD1) are thought to promote cancer, it can also associate
with the Kap1 co-repressor to inhibit gene expression (36). The breadth and biological
significance of the genes that are negatively regulated by Stat3 are not clear, but they may
play an important role in the anti-apoptotic function of mutationally activated N-Ras.
Our finding that N-Ras is unique among the Ras family members in its ability to bind Stat3
is not surprising, as other Ras family members also have unique binding partners. Galectins,
for example, are a family of proteins that are characterized by their ability to bind β-
galactoside. Mutant H-Ras binds galectin-1 more efficiently than does mutant K-Ras and
this interaction stimulates RAF activation at the expense of PI3K activation (37).
Conversely, activated K-Ras binds more efficiently to galectin-3, resulting in prolonged
activation of RAF and attenuation of PI3K and RAL signaling (38, 39). We speculate that
isoform-specific downstream effectors account, at least in part, for the functional differences
among Ras family members.
Why is N-Ras the only family member that can interact with and activate Stat3? Each Ras
family member is subjected to a different pattern of and palmitoylation within its
hypervariable region (40). These post-translational modifications affect the trafficking of
Ras family members through the cell, as well as their overall steady-state localization.
Within membranes, Ras family members have been found to localize to distinct
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microdomains in a manner that is dependent upon their nucleotide binding state. N-
Ras•GTP, for example, was found in cholesterol-rich lipid rafts, while H-Ras•GTP localized
to disordered membrane (23, 24). In our study, we failed to detect N-Ras in LYN-positive
lipid raft fractions in CRC cells, but we did find that N-Ras and H-Ras purified in distinct
membrane fractions (Fig. 4B). Moreover, disruption of cholesterol-rich microdomains via
treatment with filipin or MβCD abrogates resistance to apoptosis in cells expressing N-
RasG12D (Fig. 4C), indicating that microdomain localization is a major determinant
underlying the unique anti-apoptotic phenotype of mutant N-Ras. As such, this subtle
feature of Ras localization becomes of central importance to the oncogenic function of this
protein.
Our studies clearly establish that N-Ras, unlike K-Ras and H-Ras, can suppress stress-
induced apoptosis because it activates a non-canonical MAPK pathway. A major question
resulting from this observation is whether this mechanism can be taken advantage of as a
therapeutic strategy. In human cell lines, pharmacologic inhibition of MEK abrogated the
anti-apoptotic function of mutant N-Ras (Fig. 6A). Two recent studies of large human cell
line panels also connected N-Ras mutation to sensitivity to MEK inhibitors (41, 42). We
also found that inhibition of MEK induced apoptosis in primary mouse tumors expressing
mutant N-Ras (Fig. 6B), providing a critical in vivo validation of the in vitro results. These
observations suggest that MEK inhibitors may be useful in the clinic to treatment patients
with N-Ras mutant CRC. This result is especially significant because, as we have
demonstrated previously, CRCs expressing mutant K-Ras are not sensitive to MEK
inhibition (6).
Taken together, these experiments connect the anti-apoptotic function of mutationally
activated N-Ras to its oncogenic potential. Moreover, while we have demonstrated that
mutation of N-Ras affects the survival of CRC patients, our biochemical data suggest a
viable therapeutic strategy – inhibition of MAPK signaling – for these patients.
METHODS
Human Studies
Clinical data were collected on patients under protocols approved by the Institutional
Review Boards of MSKCC and the MGH. Tumor associated mutations were identified as
previously described (9). Gene set enrichment analysis (GSEA) was performed as described
(43) on published RNAseq data from The Cancer Genome Atlas (TCGA) (44). Individual
samples were separated based on their KRAS, NRAS, and BRAF genotypes. The gene set
corresponding to 39 targets down-regulated by Stat3 was manually collated from (45).
Induction of Colitis and Cancer in Mice
All experiments involving animals were approved by the MGH Subcommittee on Research
Animal Care. Animals expressing K-RasG12D and N-RasG12D in the intestinal epithelium
were previously described (6). Intestine-specific activation of Ras was achieved by crossing
to Villin-Cre, which directs expression of Cre recombinase to all crypts of the small
intestinal and colonic epithelia (46). Eight-week-old mice were used in all experiments.
To stimulate colitis, mice were treated with 5 or 9 cycles of 2.5% DSS in the drinking water
(5 days on, followed by 10 days off). Mice were weighed on a daily basis and colonoscopy
was performed to monitor disease progression. At the end of the treatment, mice were
sacrificed and tumor number was assessed by macroscopic examination of the dissected
colon. The tissue was then fixed overnight in 10% formalin and processed for histologic
analyses.
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In the AOM/DSS model of inflammation-induced colon cancer, animals were treated with a
single injection of azoxymethane (AOM, 10 mg/kg) on the first day and were then exposed
to 3 cycles of 2.5% DSS (7 days on, 14 days off). Body weight was monitored daily. Five
weeks after ending the treatment period, animals were sacrificed. Tumor number was scored
by macroscopic examination of the dissected colon. The tissue was then fixed overnight in
10% formalin and processed for histologic analyses.
Mouse Colonoscopy
On the day before colonoscopy, animals were fasted for 18–24 hours during which time they
were given NuLYTELY, a bowel-cleansing solution of polyethylene glycol. Prior to the
procedure, animals were anesthetized with Avertin (250 mg/kg). After sedation, the colon
was flushed with phosphate buffered saline (PBS) to remove any remaining fecal debris.
Colonoscopy was performed using a veterinary endoscope from Karl Storz Endoscopy.
CI-1040 Treatment of Mice
CI-1040 was obtained from Pfizer. N-Ras mutant and WT mice were submitted to AOM/
DSS treatment to induce tumor formation. Tumor development was monitored by
colonoscopy and only those mice harboring tumors were selected for CI-1040 treatment.
These mice were treated with two doses/day of 100 mg/kg of CI-1040 for 7 days. At the end
of the treatment, tumors were excised and snap frozen to extract protein for western blot
analyses. The levels of apoptosis were examined by quantitative western blotting using an
antibody against cleaved-caspase 3.
Immunohistochemistry
Immunohistochemistry was performed on sections (5 μM) of paraffin embedded mouse and
human tissues. Antibodies for phospho-Histone H3 (PH3, Ser10), phospho-ERK (Thr202/
Tyr204), and phospho-Stat3 (Tyr705) were from Cell Signaling Technologies. The
monoclonal antibody against CTNNB1 was from BD Biosciences. Immunohistochemistry
was performed following manufacturers instructions for each antibody. Proliferative indices
were quantified via PH3 immunohistochemistry. The proliferative index of the normal
epithelium was determined by counting the number of PH3-positive cells per crypt. To
achieve statistical significance, at least 50 crypts were counted per sample. The proliferative
index of tumors was assessed by counting the percentage of PH3-positive epithelial cells.
Several magnification fields were analyzed to account for intra-tumoral variability.
For phospho-ERK, both human and mouse tumors were classified in accordance with the
intensity of the staining as well as the relative number of positive tumor glands. Phospho-
Stat3 scoring was only based on the intensity of the staining, since its expression was
relatively homogeneous throughout the tumors.
Cell Culture, Infections, and Apoptotic Assays
DLD-1, DKs-8, HCT-116, and HKe-3 human colorectal cancer cells have been described
(47) and were provided to us by Dr. Robert Coffey (Vanderbilt University). Their identities
were confirmed by RBD pulldown analysis (Supplementary Fig. 2). Melanoma cell lines
were provided by Dr. Lawrence Kwong (Dana Farber Cancer Institute). They were not
verified.
The pBabe retrovirus system was used to generate DKs-8 and HKe-3 cells expressing
mutant forms of Ras. The DKs-8 and DBN isogenic pair was used for all experiments,
except for those described in Supplementary Fig. S3B. Gene knockdown was achieved with
pSICOR lentiviral shRNAs (48). To analyze apoptotic responses and cell signaling, cells
were plated at 80% confluence with complete medium for 24 h and then incubated in
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medium without serum for 12 h. followed by treatment with sodium butyrate for the
indicated timeframes. Apoptotic cells were quantified using the FITC-Annexin V Apoptosis
Detection Kit I according to manufacturer’s instructions (BD Biosciences). Each experiment
was performed at least twice, with each independent trial including biological triplicates. All
statistical analyses were performed by Wilcoxon Rank Sum test using the MStat computer
program.
Real time PCR
The mRNA expression levels of Stat3 targets were measured by real time PCR. RNA was
extracted using the RNeasy mini kit (Qiagen). cDNA was synthesize using 2 μg of pure
RNA using SuperScript III Reverse transcriptase kit (Invitrogen). One μl of cDNA (diluted
1:5) was added to a 20 μl real time PCR mixture containing 1X TaqMan Universal PCR
Master Mix, No AmpErase UNG, and 1x TaqMan MGB specific probes. TaqMan
expression assays were purchased from Applied Biosystems. Standard TaqMan
thermocycling conditions were employed. Real time PCR assays were performed on three
biological replicates.
Expression Vectors
pBabe(puro)-H-RasG12V and pBabe(puro)RAF1-Y340/341D have been described
previously (49). pBabe(puro)-N-RasG12D, pBabe(puro)-N-RasG12D-H-HVR, pBabe(puro)-
H-RasG12V-N-HVR, pBabe(puro)-RAF1-22W, pBabe(puro)-B-RAF, and pBabe(puro)-A-
RAF-Y304/305D were generated for this study. The Ras effector loop domain mutants
T35S, E37G, and Y40C were generated in pBabe-N-RasG12D by site-directed mutagenesis.
shRNAs for N-Ras, Stat3, A-RAF, B-RAF, and RAF-1 were designed with
pSICOoligomaker and then cloned into pSicoR (48). Target sequences for specific shRNAs
are listed in Supplementary Table S2.
Membrane Fractionations
Cellular fractionation was carried out using the simplified method for the preparation of
detergent-free lipid rafts described by Macdonald and Pike (50). Briefly, cells were seeded
in 150mm dishes at similar densities. When the cells were approximately 90% confluent,
protein was extracted following the protocol described by Macdonald et al. Fifty μl of each
fraction were used to analyze the distribution of N-Ras, H-Ras, ERK, Stat3, Caveolin 1,
LYN, and Transferrin receptor by quantitative western blotting.
Drug Treatments
AZ-628 was obtained from AstraZeneca. Cells were pre-treated with AZ-628 (1 μM) for
one hour prior to treatment with butyrate or isolation of protein. Filipin and MβCD were
purchased from Sigma. In specified experiments, cells were transiently treated with filipin (1
μg/ml) or MβCD (10 mM) for 2 hours, at which point the medium was replaced with serum-
free medium +/− sodium butyrate (3 mM).
Immunoblotting and GTPase Activity Assays
For western blotting, protein lysates were harvested with RIPA buffer. Quantitative western
blots were performed using the LiCor Odyssey. Antibodies to the following proteins were
used: ERK1/2, phospho-ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), AKT, phospho-AKT
(Ser473), JNK, phospho-JNK (Thr183/Tyr185), p38 MAPK, phospho-p38 MAPK (Thr180/
Tyr182), Stat3, and phospho-Stat3 (Tyr705 or Ser727) from Cell Signaling Technology.
Additional antibodies included, β-tubulin from Sigma and N-Ras, H-Ras, K-Ras, A-RAF, B-
RAF, and RAF-1 from Santa Cruz Biotechnology. Secondary antibodies were from LiCor.
Ras and RAL activities were assessed with assay kits from Millipore. For N-Ras activity, N-
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Ras-specific antibody was used. For RAL, the RALA antibody included with the kit was
used.
Immunoprecipitations
For immunoprecipitations, protein lysates were collected in 1X cell lysis buffer (Cell
Signaling Technology). Immobilized Stat3 (79D7) rabbit antibody was used to purify Stat3
complexes from lysates. For immunoprecipitation of N-Ras, a mouse monoclonal antibody
was used (Santa Cruz Biotechnology).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Little is known about N-Ras function in normal biology or in cancer. Our study links the
anti-apoptotic function of mutant N-Ras to its ability to promote colorectal cancer in an
inflammatory context. In addition, our study pinpoints a therapeutic strategy for this
distinct colorectal cancer subtype.
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Mutant N-RAS promotes colon cancer in the context of inflammation. A. Colonoscopy
images from mice before and after 9 cycles of DSS. WT and N-RasG12D colons looked
identical prior to treatment. After 9 cycles of DSS, WT animals developed severe colitis,
which was often associated with bleeding ulcers (black arrow), but never developed tumors.
After the same period of time, 50% of N-Ras mutant animals developed colonic tumors
(outlined in yellow). B. Histologic analysis of tissue damage in WT and N-Ras mutant
animals after 9 cycles of DSS. The WT animals exhibited more significant tissue damage. C.
Histologic analysis of colonic tumors from animals expressing N-RasG12D. These tumors
were adenocarcinomas with high-grade dysplasia. The lesions were strongly positive for
nuclear β-catenin (Ctnnb1). D. Colonic tumor multiplicities from animals treated with AOM
and DSS. WT animals (N = 7) developed, on average, 0.85 tumors per animal, while N-Ras
mutant animals (N = 12) developed, on average 2.25 tumors. (p = 0.02, Wilcoxon Rank Sum
test). E. Histologic analysis of tumors from AOM/DSS treated animals. There was no clear
difference between WT and N-Ras mutant tumors. F. Immunohistochemical detection of
apoptosis in AOM/DSS tumors. Tumors expressing wild-type N-Ras exhibited a greater
number of cells positive for cleaved caspase 3 (CC3).
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Mutant N-Ras signals through RAF-1 to confer resistance to apoptosis induced by sodium
butyrate. A. Apoptotic phenotypes of colon cancer cell lines with mutant forms of Ras. Cells
expressing wild-type Ras or H-RasG12V were sensitive to induction of apoptosis by sodium
butyrate (NaBu, 3 mM for 24 hours). Retroviral expression of N-RasG12D conferred
resistance, while endogenous K-RasG13D conferred hyper-sensitivity. It should be noted that
codon 13 mutations in Ras have been shown to elicit attenuated transforming activity when
compared to codon 12 mutations. B. Canonical effector pathway signaling in cells
expressing mutant Ras. Quantitative western blotting revealed that mutant K-Ras, N-Ras,
and H-Ras activated ERK, while only N-Ras and H-Ras activated AKT. For ERK, AKT,
JNK, and p38, activation was measured as the ratio of phospho to total protein. For RALA,
activation was measured as the ratio of GTP-bound protein to total protein. C. Apoptotic
phenotypes of colon cancer cell lines that express N-RasG12D secondarily mutated within the
effector binding domain. Like N-RasG12D, N-RasG12D/T35S conferred resistance to butyrate-
induced apoptosis. D. Requirement of RAF for the anti-apoptotic phenotype of N-RasG12D.
Treatment of WT cells with AZ-628 did not affect the response to butyrate, but inhibition of
RAF in cells expressing N-RasG12D reverted the anti-apoptotic phenotype. E. Effect of RAF
knockdown on N-RasG12D function. Cells expressing N-RasG12D required RAF-1, but not
A-RAF or B-RAF, to fully suppress butyrate-induced apoptosis. F. Apoptotic phenotypes of
colon cancer cell lines that express mutant forms of RAF. RAF-1Y340/341D fully
phenocopied N-RASG12D. Mutationally activated A-RAF (Y304/305D) and wild-type B-
RAF (which has high endogenous kinase activity due to aspartic acid substitutions at the
analogous positions) did not suppress butyrate-induced apoptosis. G. ERK activation by
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mutant RAF. A-RAF, B-RAF, and RAF-1 all activated ERK to the same extent. ERK
activation was measured by quantitative western blotting. In all panels, Error bars ± SEM.
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Mutant N-Ras signals through Stat3 to confer resistance to apoptosis induced by sodium
butyrate. A. Effect of exogenous IL-6 on butyrate-induced apoptosis. IL-6 significantly
suppressed apoptosis in WT cells, but failed to do so in cells expressing N-RasG12D. B.
Activation of Stat3 by mutant N-Ras and RAF-1. Expression of N-RasG12D or
RAF-1Y340/341D led to hyper-phosphorylation of Stat3 at a positive regulatory site, Tyr705.
Stat3 activation was determined by quantitative western blotting. C. Expression of Stat3
target genes. Two genes known to be up-regulated by activated Stat3, CCND1 and SOCS3,
were also up-regulated in cells expressing N-RasG12D. Two genes known to be down-
regulated by activated Stat3, IFIT3 and IFI35, were also down-regulated in cells expressing
N-RasG12D. D. Effect of Stat3 knockdown on N-RasG12D anti-apoptotic function. Cells
expressing N-RasG12D required Stat3 to fully suppress butyrate-induced apoptosis. E. Effect
of Stat3 inhibition on N-RasG12D anti-apoptotic function. Treatment of WT cells with
Stattic, a small molecule Stat3 inhibitor, did not significantly affect the response to butyrate.
Inhibition of Stat3 in cells expressing N-RasG12D reverted the anti-apoptotic phenotype. F.
Effect of MEK inhibition on Stat3 activation. Treatment with CI-1040 decreased Stat3
phosphorylation on Tyr705 (p = 0.06, Wilcoxon Rank Sum test). The phosphorylation of
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ERK was measured as a control for the activity of the MEK inhibitor. G. N-Ras interacts
with Stat3. α-Stat3 antibody was able to immunoprecipitate both Stat3 and N-Ras in cells
expressing N-RasG12D. This complex was dependent upon the presence of Stat3, N-Ras, and
RAF-1. Transient exposure to filipin negatively affected complex formation. In this
experiment, in order to control for the overall amount of N-Ras expressed in cells, “WT”
denotes cells that ectopically over-express wild-type N-Ras. In panels A–F, Error bars ±
SEM.
Wang et al. Page 21














N-Ras signals from a distinct membrane compartment to suppress apoptosis. A. Effects of
hypervariable region (HVR) replacement on apoptotic phenotypes of CRC cell lines with
mutant forms of Ras. Replacing the N-Ras HVR with that of H-Ras (H-HVR) conferred
sensitivity to induction of apoptosis by sodium butyrate. Conversely, replacing the H-Ras
HVR with that of N-Ras (N-HVR) conferred resistance to apoptosis. B. Biochemical
fractionation of plasma membranes. Mutant N-Ras was found primarily in fractions 11–17,
while mutant H-Ras was found primarily in fractions 8–12. ERK and Stat3, like N-Ras, were
enriched in later fractions. The composition of specific fractions was confirmed by positivity
for caveolin, LYN, and/or transferrin receptor (TfR). C. N-Ras function requires cholesterol-
rich microdomains. Transient treatment with filipin (1 μg/ml for 2 hours) or MβCD (10 mM
for 2 hours) abrogated the anti-apoptotic phenotype of mutant N-Ras, but did not affect the
response of WT cells to sodium butyrate. In panels A and C, Error bars ± SEM.
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Activation of ERK and Stat3 in primary tumors expressing mutant N-Ras. A.
Immunohistochemistry for phospho-ERK in autochthonous mouse and human tumors. B.
Quantification of phospho-ERK staining in primary tumors. Staining was considerably less
variable in mouse tumors. (N = 10 for WT mouse tumors, N = 7 for N-RasG12D mouse
tumors, N = 17 for WT human cancers, N = 19 for NRAS mutant human cancers) C.
Enrichment plot for NRAS mutant CRC. Genes related to ERK signaling were significantly
enriched in cancers expressing mutant N-Ras. D. Immunohistochemistry for phospho-Stat3
in autochthonous mouse and human tumors. E. Evaluation of phospho-Stat3 staining in
primary colonic tumors from animals treated with AOM/DSS. (N = 10 for WT tumors, N =
8 for N-RasG12D tumors, N = 17 for WT human cancers, N = 19 for NRAS mutant human
cancers) F. Enrichment plot for NRAS mutant CRC. Genes down-regulated by Stat3 were
negatively enriched in cancers expressing mutant N-Ras.
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Inhibition of MEK as a therapeutic strategy for N-Ras mutant CRC. A. Requirement of
MEK for the anti-apoptotic phenotype of N-RasG12D in human cell lines. Treatment of WT
cells with CI-1040 did not significantly affect the response to butyrate. Inhibition of MEK in
cells expressing N-RasG12D reverted the anti-apoptotic phenotype. B. Induction of apoptosis
in primary mouse tumors by treatment with CI-1040. Generally, WT tumors did not respond
to inhibition of MEK. By contrast, the majority of tumors expressing N-RasG12D exhibited
detectable levels of apoptosis. Apoptosis was detected by quantitative western blotting for
cleaved caspase 3 (CC3). (N = 10 for mock-treated WT tumors, N = 9 for treated WT
tumors, N = 12 for mock-treated N-Ras mutant tumors, N = 11 for treated N-Ras mutant
tumors) C. NRAS mutation correlates with worse overall survival in CRC patients. Kaplan-
Meier plot of overall survival for 314 patients (17 NRAS mutant and 297 NRAS/KRAS/
BRAF wild-type) with CRC (stages 1–4). The survival of patients with KRAS mutant CRC
in this cohort is shown for comparison. The difference in survival is statistically significant
(p= 0.004, log-rank test). Of the NRAS mutant cases, 10/17 were stage 4. For WT cases,
134/297 were stage 4. This difference is not statistically significant (p = 0.3). In panels A
and B, Error bars ± SEM.
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